![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GALT |
Gene summary for GALT |
![]() |
Gene information | Species | Human | Gene symbol | GALT | Gene ID | 2592 |
Gene name | galactose-1-phosphate uridylyltransferase | |
Gene Alias | GALT | |
Cytomap | 9p13.3 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | A0A0S2Z3Y7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2592 | GALT | LZE4T | Human | Esophagus | ESCC | 7.97e-06 | 2.81e-01 | 0.0811 |
2592 | GALT | LZE24T | Human | Esophagus | ESCC | 4.81e-06 | 1.73e-01 | 0.0596 |
2592 | GALT | LZE21T | Human | Esophagus | ESCC | 8.53e-04 | 1.81e-01 | 0.0655 |
2592 | GALT | P2T-E | Human | Esophagus | ESCC | 3.02e-33 | 6.77e-01 | 0.1177 |
2592 | GALT | P4T-E | Human | Esophagus | ESCC | 2.83e-07 | 1.24e-01 | 0.1323 |
2592 | GALT | P5T-E | Human | Esophagus | ESCC | 5.98e-12 | 1.18e-01 | 0.1327 |
2592 | GALT | P8T-E | Human | Esophagus | ESCC | 1.07e-08 | 1.11e-01 | 0.0889 |
2592 | GALT | P9T-E | Human | Esophagus | ESCC | 1.63e-07 | 1.68e-01 | 0.1131 |
2592 | GALT | P10T-E | Human | Esophagus | ESCC | 7.34e-15 | 1.24e-01 | 0.116 |
2592 | GALT | P11T-E | Human | Esophagus | ESCC | 2.44e-09 | 2.49e-01 | 0.1426 |
2592 | GALT | P12T-E | Human | Esophagus | ESCC | 5.82e-15 | 3.15e-01 | 0.1122 |
2592 | GALT | P15T-E | Human | Esophagus | ESCC | 3.94e-04 | 9.08e-02 | 0.1149 |
2592 | GALT | P16T-E | Human | Esophagus | ESCC | 3.62e-17 | 2.07e-01 | 0.1153 |
2592 | GALT | P17T-E | Human | Esophagus | ESCC | 7.72e-08 | 1.96e-01 | 0.1278 |
2592 | GALT | P20T-E | Human | Esophagus | ESCC | 6.95e-04 | 1.30e-01 | 0.1124 |
2592 | GALT | P21T-E | Human | Esophagus | ESCC | 1.04e-19 | 2.55e-01 | 0.1617 |
2592 | GALT | P22T-E | Human | Esophagus | ESCC | 2.72e-23 | 2.85e-01 | 0.1236 |
2592 | GALT | P23T-E | Human | Esophagus | ESCC | 5.09e-15 | 1.48e-01 | 0.108 |
2592 | GALT | P24T-E | Human | Esophagus | ESCC | 5.85e-09 | 7.34e-02 | 0.1287 |
2592 | GALT | P26T-E | Human | Esophagus | ESCC | 1.33e-18 | 1.76e-01 | 0.1276 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
GO:00100015 | Oral cavity | OSCC | glial cell differentiation | 110/7305 | 225/18723 | 1.56e-03 | 7.45e-03 | 110 |
GO:00442826 | Oral cavity | OSCC | small molecule catabolic process | 174/7305 | 376/18723 | 2.25e-03 | 1.00e-02 | 174 |
GO:0050650 | Oral cavity | OSCC | chondroitin sulfate proteoglycan biosynthetic process | 16/7305 | 23/18723 | 2.93e-03 | 1.27e-02 | 16 |
GO:00066641 | Oral cavity | OSCC | glycolipid metabolic process | 53/7305 | 100/18723 | 3.09e-03 | 1.33e-02 | 53 |
GO:19035091 | Oral cavity | OSCC | liposaccharide metabolic process | 53/7305 | 101/18723 | 4.06e-03 | 1.66e-02 | 53 |
GO:00447067 | Oral cavity | OSCC | multi-multicellular organism process | 105/7305 | 220/18723 | 5.05e-03 | 1.97e-02 | 105 |
GO:19030531 | Oral cavity | OSCC | regulation of extracellular matrix organization | 28/7305 | 48/18723 | 5.17e-03 | 2.02e-02 | 28 |
GO:0006672 | Oral cavity | OSCC | ceramide metabolic process | 53/7305 | 102/18723 | 5.28e-03 | 2.06e-02 | 53 |
GO:00160513 | Oral cavity | OSCC | carbohydrate biosynthetic process | 97/7305 | 202/18723 | 5.50e-03 | 2.13e-02 | 97 |
GO:001605210 | Oral cavity | OSCC | carbohydrate catabolic process | 76/7305 | 154/18723 | 5.67e-03 | 2.18e-02 | 76 |
GO:0030204 | Oral cavity | OSCC | chondroitin sulfate metabolic process | 19/7305 | 30/18723 | 6.03e-03 | 2.28e-02 | 19 |
GO:0030148 | Oral cavity | OSCC | sphingolipid biosynthetic process | 53/7305 | 103/18723 | 6.81e-03 | 2.53e-02 | 53 |
GO:00600553 | Oral cavity | OSCC | angiogenesis involved in wound healing | 19/7305 | 31/18723 | 9.93e-03 | 3.48e-02 | 19 |
GO:00442625 | Oral cavity | OSCC | cellular carbohydrate metabolic process | 130/7305 | 283/18723 | 9.98e-03 | 3.49e-02 | 130 |
GO:006156410 | Oral cavity | OSCC | axon development | 207/7305 | 467/18723 | 1.01e-02 | 3.51e-02 | 207 |
GO:003465518 | Oral cavity | LP | nucleobase-containing compound catabolic process | 161/4623 | 407/18723 | 1.61e-11 | 1.15e-09 | 161 |
GO:001943916 | Oral cavity | LP | aromatic compound catabolic process | 176/4623 | 467/18723 | 1.96e-10 | 1.08e-08 | 176 |
GO:004427017 | Oral cavity | LP | cellular nitrogen compound catabolic process | 170/4623 | 451/18723 | 3.93e-10 | 2.02e-08 | 170 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012505 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
hsa005202 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
hsa0125012 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
hsa0052011 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa049171 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa00520 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
hsa012504 | Oral cavity | OSCC | Biosynthesis of nucleotide sugars | 25/3704 | 37/8465 | 2.93e-03 | 7.49e-03 | 3.81e-03 | 25 |
hsa005201 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
hsa0125011 | Oral cavity | OSCC | Biosynthesis of nucleotide sugars | 25/3704 | 37/8465 | 2.93e-03 | 7.49e-03 | 3.81e-03 | 25 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GALT | insertion | Frame_Shift_Ins | novel | c.550_551insCTTTTCCAAGCAAAGTCTGCTCGAGGAGTCTGGT | p.His184ProfsTer30 | p.H184Pfs*30 | P07902 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
GALT | SNV | Missense_Mutation | novel | c.268N>A | p.Asp90Asn | p.D90N | P07902 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GALT | SNV | Missense_Mutation | novel | c.46G>C | p.Glu16Gln | p.E16Q | P07902 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.703) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GALT | SNV | Missense_Mutation | novel | c.877T>G | p.Ser293Ala | p.S293A | P07902 | protein_coding | deleterious(0.04) | probably_damaging(0.945) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
GALT | SNV | Missense_Mutation | c.1078G>A | p.Ala360Thr | p.A360T | P07902 | protein_coding | tolerated(0.43) | benign(0.02) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
GALT | SNV | Missense_Mutation | rs553769637 | c.668G>A | p.Arg223His | p.R223H | P07902 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
GALT | SNV | Missense_Mutation | c.566N>C | p.Val189Ala | p.V189A | P07902 | protein_coding | deleterious(0) | benign(0.088) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GALT | SNV | Missense_Mutation | c.507N>T | p.Gln169His | p.Q169H | P07902 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
GALT | SNV | Missense_Mutation | rs553769637 | c.668G>A | p.Arg223His | p.R223H | P07902 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GALT | SNV | Missense_Mutation | rs111033686 | c.413N>T | p.Thr138Met | p.T138M | P07902 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-DC-6154-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2592 | GALT | ENZYME | HyperAcute vaccine | |||
2592 | GALT | ENZYME | Algenpantucel-L | ALGENPANTUCEL-L | 24343588 |
Page: 1 |